Table 1.
Baseline characteristics
| Patients (n = 18) | |
|---|---|
| Age, years | 70 (62–74) |
| ECOG performance status | |
| 0 | 16 (89%) |
| 1 | 2 (11%) |
| Time from primary diagnosis, months | 30.5 (14.1–49.7) |
| Metastasis site at inclusion | |
| Bone | 17 (94%) |
| Lymph nodes | 1 (6%) |
| Other | 0 (0%) |
| Body mass index, kg/m2 | 27 (26–30) |
| Prostate-specific antigen, ng/mL | 8.4 (4.7–39.4) |
| Alkaline phosphatase, U/L | 77 (66–100) |
| Lactate dehydrogenase, U/L | 189 (174–195) |
| Number of previous therapeutic regiments, n (%) | |
| 1 | 9 (50%) |
| 2 | 4 (22%) |
| ≥ 3 | 5 (28%) |
| Prior antiandrogen + GnRH agonist or GnRH antagonist therapy | 18 (100%) |
| GnRH agonist (+ initial 4w bicalutamide) | 15 |
| GnRH antagonist | 3 |
| Prior platinum-based chemotherapy for metastatic disease | 9 (50%) |
Results are given as medians with 1st-3rd interquartile ranges in parentheses, or numbers with percentages in parentheses
ECOG = Eastern Cooperative Oncology Group performance status; U/L = units per liter; GnRH = gonadotropin-releasing hormone